Compare Amylx Pharmaceuticals Inc (AMLX) vs Hut 8 Corp (HUT) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

HUT trades at $102.22, down 3.77% over 24 hours, with a bearish technical signal and key support at $98. The company reported a net loss of $226.15 million in 2025 despite revenue growth, but recent earnings beats and a strategic pivot to AI infrastructure have driven positive analyst sentiment. Strong institutional backing is evident with $4.25 billion in project financing secured in June 2026.

Outlook remains speculative with high execution risk amid the business transition, though Wall Street consensus is bullish with a $135.63 price target. Key risks include sustained negative cash flow, competitive pressures in data centers, and reliance on successful AI project deployment to achieve profitability.